AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01334-06v1
51/4/1582    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hocquet, D.
Right arrow Articles by Plésiat, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hocquet, D.
Right arrow Articles by Plésiat, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2007, p. 1582-1583, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01334-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

MexAB-OprM- and MexXY-Overproducing Mutants Are Very Prevalent among Clinical Strains of Pseudomonas aeruginosa with Reduced Susceptibility to Ticarcillin{triangledown}


   LETTER
Top
 Letter
References
 
Of the nine efflux systems of the RND (resistance nodulation cell division) family characterized so far in Pseudomonas aeruginosa, four confer significant resistance to antibiotics when overproduced. These systems, namely, MexAB-OprM (ABM), MexCD-OprJ (CDJ), MexEF-OprN (EFN), and MexXY (XY), are individually able to pump out multiple antipseudomonal compounds, including ß-lactams (ABM, CDJ, XY), fluoroquinolones (ABM, CDJ, EFN, XY), and aminoglycosides (XY) (6). Multiresistant mutants overproducing these pumps have sporadically been described, but their prevalence in the clinical setting remains poorly known. This study was first designed to determine the proportion of ABM gain-of-efflux mutants in a collection of clinical P. aeruginosa isolates displaying reduced susceptibilities to ticarcillin (TIC). As resistance to TIC is frequently associated with resistance to aminoglycosides and to fluoroquinolones, we also assessed the expression of CDJ, EFN, and XY efflux systems in the isolates.

In 2004, 450 clinically relevant (noncystic fibrosis-associated) isolates of P. aeruginosa were collected from 450 patients hospitalized in 15 French hospitals (30 isolates from each center). The MICs of TIC, amikacin (AMK), and ciprofloxacin (CIP) were determined with the conventional agar dilution method (5), allowing the selection of a subset of 170 isolates (38%) exhibiting increased resistance to TIC (MICs ≥ 32 µg/ml). Their relative expression levels for the mexB, mexC, mexE, and mexY genes were measured in duplicate by quantitative real-time PCR, with rpsL as the housekeeping gene (1, 2). Based on previous studies (2, 3), typical MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY gain-of-efflux mutants expressed mexB, mexC, mexE, and mexY at least 2, 100, 100, and 4 times more than the wild-type reference strain PAO1, respectively.

Very high proportions of ABM (46%) and XY (58%) overproducers were found among the selected isolates, with no fewer than 28% of isolates overexpressing the two systems simultaneously. As expected, overproduction of CDJ or EFN, which is associated with hypersusceptibility to ß-lactam antibiotics (8), was absent (no CDJ mutant) or rare (one EFN mutant) in this series. Overproduction of ABM was observed in isolates with low-level resistance to TIC (MICs, 32 to 64 µg/ml) as well as in highly resistant strains (MICs ≥ 512 µg/ml) (Table 1) . Similarly, overproduction of ABM and/or XY was associated with low-level resistance to CIP (MICs, 0.25 to 0.5 µg/ml) but was also very common (up to 100% for MexXY) in more-resistant strains (MICs ≥ 2 µg/ml) (7) (Table 1). Finally, overproduction of XY was observed in a large proportion of isolates displaying either low-level (MICs, 8 to 16 µg/ml) or high-level (MICs ≥ 32 µg/ml) resistance to AMK. Since when upregulated, systems ABM and XY provide only moderate resistance to their respective substrates (MICs increased two- to eightfold) (6), it is likely that additional mechanisms were also present in the most resistant strains (e.g., production of ß-lactamases or aminoglycoside-modifying enzymes, alteration of fluoroquinolone targets).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Prevalence of isolates overexpressing mexAB-oprM and mexXY in relation to levels of resistance to TIC, CIP, or AMK

 
Efforts have been made over the past years for the development of efflux pump inhibitors active on the Mex pumps in P. aeruginosa (4). Our present results highlight the urgent need for inhibitors targeting with priority the two most prevalent efflux systems in clinical isolates, namely, ABM and XY.


   ACKNOWLEDGMENTS
 
This work was supported by a grant from Wyeth Pharmaceuticals.

We are grateful to Barbara Dehecq for her excellent technical work. We also thank the other members of the GERPA group (Groupe d'Etude de la Résistance de Pseudomonas aeruginosa) for their participation to this study: C. Bébéar (CHR Pellegrin, Bordeaux, France), R. Bismuth (Pitié-Salpétrière, Paris, France), P. Brisou (HIA St Anne, Toulon, France), J. Caillon (CHU Laennec, Nantes, France), R. Fabre (HIA Bégin Saint-Mandé, France), C. Chanal (CHU Gabriel-Montpied, Clermond-Ferrand, France), M. Chomarat (CHU Lyon Sud, Pierre-Bénite, France), R. Leclercq (CHRU Côte-de-Nacre, Caen, France), H. Marchandin (CHU Arnaud-de-Villeneuve, Montpellier, France), C. Muller (CHU Bichat-Claude-Bernard, Paris, France), C. Poyart (CHU Cochin, Paris, France), F. Delpierre (CHRU Calmette, Lille, France), C. Segonds (CHU Rangueil, Toulouse, France), and J. M. Scheftel (Hôpitaux universitaires, Strasbourg).


   FOOTNOTES
 
{triangledown} Published ahead of print on 12 January 2007. Back


   REFERENCES
Top
 Letter
 References
 

  1. Dumas, J. L., C. Delden, K. Perron, and T. Köhler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.[CrossRef][Medline]
  2. Hocquet, D., P. Nordmann, F. El Garch, L. Cabanne, and P. Plésiat. 2006. Involvement of the efflux system MexXY-OprM in the emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1347-1351.[Abstract/Free Full Text]
  3. Llanes, C., D. Hocquet, C. Vogne, D. Bénali-Baitich, C. Neuwirth, and P. Plésiat. 2004. Clinical strains of Pseudomonas aeruginosa overproducing simultaneously MexAB-OprM and MexXY efflux pumps. Antimicrob. Agents Chemother. 48:1797-1802.[Abstract/Free Full Text]
  4. Lomovskaya, O., M. S. Warren, A. Lee, J. Galazzo, R. Fronko, M. Lee, J. Blais, D. Cho, S. Chamberland, T. Renau, R. Leger, S. Hecker, W. Watkins, K. Hoshino, H. Ishida, and V. J. Lee. 2001. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother. 45:105-116.[Abstract/Free Full Text]
  5. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 6th ed. M7, A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
  6. Piddock, L. J. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402.[Abstract/Free Full Text]
  7. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob. Agents Chemother. 44:2233-2241.[Free Full Text]
  8. Poole, K. 2002. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa, p. 201-231. In I. T. Paulsen and K. Lewis (ed.), Microbial multidrug efflux. Horizon Scientific Press, Wymondham, United Kingdom.
Didier Hocquet*
Laboratoire de Bactériologie
Centre National de Référence de la Résistance
aux antibiotiques (P. aeruginosa)
Hôpital Jean Minjoz
University of Franche-Comté
25030 Besançon Cedex, France

Micheline Roussel-Delvallez
Laboratoire de Bactériologie
CHRU
Hôpital Calmette
59037 Lille Cedex, France

Jean-Didier Cavallo
Laboratoire de Microbiologie Clinique
Hôpital d'Instruction des Armées Bégin
94163 Saint-Mandé Cedex, France

Patrick Plésiat
Laboratoire de Bactériologie
Centre National de Référence de la Résistance
aux antibiotiques (P. aeruginosa)
Hôpital Jean Minjoz
University of Franche-Comté
25030 Besançon Cedex, France

* Phone: (33) 3 81 66 82 86, Fax: (33) 3 81 66 89 14, E-mail: dhocquet{at}chu-besancon.fr

Antimicrobial Agents and Chemotherapy, April 2007, p. 1582-1583, Vol. 51, No. 4
0066-4804/07/$08.00+0     doi:10.1128/AAC.01334-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.01334-06v1
51/4/1582    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hocquet, D.
Right arrow Articles by Plésiat, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hocquet, D.
Right arrow Articles by Plésiat, P.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS